Platinum International Brands Fund sold the bulk of its Zoetis holding after the animal-health company’s shares tumbled 35% during the quarter, calling the investment a mistake. The fund said rivals have caught up to Zoetis’s once-dominant franchises in canine dermatology and parasiticides, and its commercial response has disappointed. A social-media scare campaign derailed the US launch of a new arthritis treatment, which the fund attributed to inadequate commercial execution. While acknowledging Zoetis’s strong research engine and pipeline, the fund noted the next launch is at least a year away. Zoetis closed at $77.51 on July 28, 2026, with a market capitalization of about $32.49 billion, and its shares have lost nearly 48% over the past 52 weeks.
Zoetis IncRivals have caught up to Zoetis's once-dominant franchises in canine dermatology and parasiticides, and its commercial response has disappointed.